Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

FDA approves once-daily Ryzolt for moderate to moderately severe pain

Jan. 7, 2009

King provides update on Embeda NDA review

Jan. 7, 2009

Acura and King Pharmaceuticals submit NDA to FDA for Acurox anti-abuse opioid analgesic

Jan. 7, 2009

IGF-1 does not affect outcome measures in phase III amyotrophic lateral sclerosis trial

Jan. 7, 2009

New mgluR2 ligands/5-HT2A antagonists described in Abbott patent

Jan. 5, 2009

Urigen amends licence agreement with UCSD for URG-101

Jan. 5, 2009

FDA issues complete response letter to Ipsen for Dysport BLA in cervical dystonia

Jan. 5, 2009

Sosei reacquires commercialization rights to opioid analgesic AD-923 from Mundipharma

Jan. 5, 2009

King commences phase II T-62 trial in neuropathic pain

Dec. 31, 2008

Neuren discontinues Glypromate development following pivotal trial

Dec. 31, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 22, 2026.
Alicorn synthesizes new AAK1 inhibitors
BioWorld Science
Researchers from Alicorn Pharmaceutical Co. Ltd. and Jiangsu Alicorn Pharmaceutical Co. Ltd. have disclosed crystalline salts of compounds acting as...
CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research
BioWorld Science
Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...
Saniona reports preclinical data for SAN-2668
BioWorld Science
Saniona AB has presented preclinical data and its clinical development strategy for its lead clinical candidate, SAN-2668, which is a GABA-A receptor positive...
Insilico Medicine synthesizes new Nav1.8 blockers
BioWorld Science
Insilico Medicine Inc. has identified sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers that are potentially useful for the treatment of pain.